RVMD
Revolution Medicines, Inc.
NASDAQ · USHealthcareBiotechnology
$180.39-3.10%
Price as of Jul 20, 2026
RVMD financials
Revolution Medicines, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $0.00 | $11.6M | $35.4M |
| Cost of revenue | $16.6M | $0.00 | $0.00 | $0.00 |
| Gross profit | -$16.6M | $0.00 | $11.6M | $35.4M |
| Operating expenses | $1.2B | $689.5M | $498.8M | $293.7M |
| Operating income | -$1.2B | -$689.5M | -$487.2M | -$258.3M |
| Net income | -$1.1B | -$600.1M | -$436.4M | -$248.7M |
| EBITDA | -$1.1B | -$589.0M | -$430.3M | -$239.5M |
| Basic EPS | $-5.95 | $-3.58 | $-3.86 | $-3.08 |
| Diluted EPS | $-5.95 | $-3.58 | $-3.86 | $-3.08 |
| Balance sheet | ||||
| Cash & equivalents | $383.7M | $543.1M | $696.1M | $161.4M |
| Total assets | $2.4B | $2.6B | $2.1B | $811.9M |
| Total liabilities | $723.2M | $293.1M | $235.5M | $126.7M |
| Stockholders’ equity | $1.6B | $2.3B | $1.8B | $685.2M |
| Total debt | $158.7M | $135.8M | $87.9M | $64.2M |
| Net debt | -$225.0M | -$407.2M | -$608.2M | -$97.2M |
| Cash flow | ||||
| Operating cash flow | -$897.7M | -$557.4M | -$350.6M | -$224.4M |
| Capital expenditure | -$16.0M | -$10.3M | -$7.7M | -$10.8M |
| Free cash flow | -$913.7M | -$567.7M | -$358.3M | -$235.2M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |